The German pharmaceutical company behind the COVID-19 Pfizer vaccine is now embarking on a project to create another vaccine, aimed at eradicating Malaria in African countries, and to implement vaccine supply solutions.
“We are more than grateful to be part of the joint efforts of the Eradicate Malaria project,” says Prof. Dr. Ugur Sahin, CEO, and co-founder of BioNTech. “Our efforts will include cutting-edge research and innovation, significant investments in vaccine development, the establishment of manufacturing facilities, and the transfer of manufacturing expertise to production sites on the African continent and wherever else it is needed.”
BioNTech is developing an mRNA vaccine that offers immunity against Malaria. The pharmaceutical company also wishes to expand the capacity of low and middle-income countries to manufacture their vaccine supplies, meaning that the production would scale-up and the global access would be increased on African territories. As part of the ‘eradicate Malaria’ initiative led by the kENUP Foundation, BioNTech hopes to accelerate the elimination of the deadly disease.